(VIANEWS) – SANOFI (SAN.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| SANOFI (SAN.PA) | €87.57 | 4.08% | 7.27% |
| VISTIN PHARMA (VISTN.OL) | kr22.90 | 3.11% | 16.03% |
| TUBIZE-FIN (TUB.BR) | €88.50 | 0.99% | 4.93% |
| BIOMERIEUX (BIM.PA) | €99.84 | 0.83% | 9.87% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. SANOFI (SAN.PA)
4.08% Forward Dividend Yield and 7.27% Return On Equity
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €4.3.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 20.37. Meaning, the purchaser of the share is investing €20.37 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.27%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 19% and a negative 3.4%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SANOFI’s EBITDA is 2.55.
More news about SANOFI.
2. VISTIN PHARMA (VISTN.OL)
3.11% Forward Dividend Yield and 16.03% Return On Equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 22.9. Meaning, the purchaser of the share is investing kr22.9 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.03%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 30.8%, now sitting on 438.54M for the twelve trailing months.
Sales Growth
VISTIN PHARMA’s sales growth is 10.6% for the current quarter and 6.6% for the next.
Yearly Top and Bottom Value
VISTIN PHARMA’s stock is valued at kr22.90 at 01:30 EST, below its 52-week high of kr25.10 and way above its 52-week low of kr16.30.
More news about VISTIN PHARMA.
3. TUBIZE-FIN (TUB.BR)
0.99% Forward Dividend Yield and 4.93% Return On Equity
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. The company is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €2.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 44.25. Meaning, the purchaser of the share is investing €44.25 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.93%.
Volume
Today’s last reported volume for TUBIZE-FIN is 10794 which is 8.38% below its average volume of 11782.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on May 3, 2023, the estimated forward annual dividend rate is 0.86 and the estimated forward annual dividend yield is 0.99%.
More news about TUBIZE-FIN.
4. BIOMERIEUX (BIM.PA)
0.83% Forward Dividend Yield and 9.87% Return On Equity
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Earnings Per Share
As for profitability, BIOMERIEUX has a trailing twelve months EPS of €3.25.
PE Ratio
BIOMERIEUX has a trailing twelve months price to earnings ratio of 30.72. Meaning, the purchaser of the share is investing €30.72 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.87%.
More news about BIOMERIEUX.
